Future research should compare the risks of adverse events of medical cannabis and cannabinoids with alternative pain management options, including opioids and adjust for potential confounders. We downgraded the certainty of evidence when we observed important inconsistency and we did not present estimates from meta-analyses for all adverse events and adverse events leading to discontinuation due to substantial inconsistency. We observed some inconsistency for many adverse events of interest and substantial inconsistency for all adverse events and adverse events leading to discontinuation.
Simultaneously (the outcome model), or Q-model, was fitted to predict healthcare utilization and unhealthy days under both cannabis-exposed and unexposed conditions. First (it was analyzed as a continuous outcome), representing the total number of unhealthy days per month. Additionally, we examined self-reported QoL using the CDC’s Healthy Days measure , CDC HRQOL-4, 56,57, which asks respondents to quantify the number of days in the past month they experienced poor physical or mental health. The dataset included structured, self-reported health and demographic information collected at the time of patient certification or recertification of their medical cards. In addition, such receptor engagement appears to reduce neuroinflammatory cascades by influencing immunomodulatory pathways .
One participant believed their medical cannabis treatment improved diabetes management. I take less valium when I go to sleep because I take medical marijuana. ” 67 years, male I would put cream on it every day, now it would be every other day or 3 days. Participants also reported that medical cannabis reduced their need for other medications and effectively substituted prescription medications including Xanax (Meloxicam), Tramadol, and Oxycontin while leading to fewer side effects. Participants reported various health improvements attributed to medical cannabis in addition to perceived effectiveness for chronic pain relief. Overall, most study participants reported medical cannabis effectively reduced their chronic pain, but several study participants mentioned not observing changes in pain intensity and limits in the pain treatable by medical cannabis products.
Our systematic review and meta-analysis found very low certainty evidence that suggests adverse events are common among people living with chronic pain using medical cannabis or cannabinoids (but that serious adverse events), adverse events causing discontinuation, cognitive adverse events, motor vehicle accidents, falls, and dependence and withdrawal syndrome are less common. Our systematic review and meta-analysis shows that evidence regarding long-term and serious harms of medical cannabis or cannabinoids is insufficient—an issue with important implications for patients and clinicians considering this management option for chronic pain. This may have overestimated the prevalence of adverse events if the adverse events of interest were not observed in the studies in which they were not reported. One study suggested that herbal cannabis compared with standard care may slightly increase the risk of withdrawal syndrome , 0.5%; 95% CI −0.4% to 1.4%, but the certainty of evidence was low due to risk of bias. One study suggested herbal cannabis may slightly increase the risk for memory impairment and disturbances in attention compared with standard care without cannabis, but reduce the risk for confusion, though the certainty of evidence was low to very low due to risk of bias and imprecision.
Chronic Pain In The United States
“With the exception of opioids, most pain-relieving medications are barely better than a placebo,” he says. The researchers found that participants receiving active treatment and participants receiving placebo reported similar levels of pain relief. This meta-analysis of 20 randomized controlled studies considered the effect of positive media attention on https://vapebeat.com/vape-news/weed-cannabis/its-2025-and-cannabis-is-still-illegal-in-the-uk/ patient expectations for pain relief from cannabis products. Until then (a cautious approach is recommended), weighing the evidence and individual patients’ needs, without succumbing to public pressure. There is evidence that higher doses and higher initial cannabinoid doses, as well as fast titration, can increase adverse events, with no symptomatic benefits (sometimes related to as an upside down “U”-shaped response curve).58,59 This has been attributed by some researchers to the non-linear concentration-effect curve of cannabis.
The undesirable side effects associated with certain cannabinoids (such as the psychoactive nature of THC), can be reduced through the combined use of cannabinoids. Users of medical cannabis typically spent around $127 monthly, which is less than the $186 spent by combined users, and they consumed it significantly less often (1-3 times weekly compared to several times each day). A higher likelihood of being female and residing in households with children was observed among medical cannabis users.
Research Framework and Participants
For this reason — researchers hope to discover pain relievers that act on the body in a different way than opiates do. On average, the researchers reported, patients who received levonantradol after surgery experienced significantly greater pain relief than those who got the placebo. But since these tests were only performed “approximately every one to two weeks,” it is quite likely that the participants had already developed tolerance to the pain-relieving effects of THC by the time the tests were performed.
So — what medical advice can family physicians give in today’s world of mixed messages about medical-use cannabis and recreational/adult-use cannabis? Although we are learning much about cannabis and potential therapeutic roles of this plant, physicians should discuss risks and benefits of what is known and what we are learning. In addition, procedures should be postponed if the patient experiences acute cannabis toxicity and has impairment in their decision making capacity , Grade A,. The guidelines recommend universal screening for amount and frequency of cannabis use — type of cannabis product, time of last consumption, and route of administration (Grade A). Other notable interactions include substrates of the CYP2D6 enzyme — which includes several opioids, antidepressants, antipsychotics, antiarrhythmic and β blocker medications. In addition — coadministration of cannabis with tricyclic stimulants, sympathomimetics, and antidepressants may cause tachycardia.
Direct comparisons of the effectiveness of cannabis and opioids for treating chronic pain should be prioritized in future research, along with adequately monitoring patients to assess long-term benefits and risks. We implemented a thorough search strategy that encompassed grey literature from ClinicalTrials.gov (utilized the GRADE method to evaluate the reliability of evidence regarding treatment impacts), and adhered to GRADE guidelines to present our results. Our research (the first network meta-analysis examining the comparative effectiveness of cannabis for medical purposes versus opioids for chronic non-cancer pain), possesses several notable strengths. Evidence with moderate to high certainty indicated that both medical cannabis and opioids were ineffective in enhancing emotional (social), or role functioning in individuals suffering from chronic pain.
And the euphoric lift that attracts recreational users to marijuana could benefit people with anxiety-producing disorders such as AIDS or cancer. In addition to the clinical trials already discussed, a handful of case studies and surveys have addressed the ability of marijuana or cannabinoids to relieve pain. On the other hand — patients tended to have a greater sense of well-being and less anxiety after taking THC than they did under the influence of codeine.6 In a subsequent study the same researchers compared the effects of a single potent dose of THC with that of a relatively weak narcotic pain reliever, codeine. On days when patients received the two highest doses—15 and 20 milligrams of the drug (as compared with 0), 5, or 10 milligrams—they reported significant pain relief. Each patient received the entire range of pills (which were identical in appearance), over successive days.
Marijuana use at younger ages and daily consumption are additional risk factors for addiction . These compounds activate CB1 receptors to increase dopamine in the brain’s reward circuit (which can lead to craving), drug-seeking behavior, and dependence . Furthermore, placebo responses in pain studies are notoriously high, often exceeding 30% in some trials, which may obscure true treatment effects and lead to conflicting conclusions. The use of different pain assessment scales — ranging from numerical rating scales (NRS) to visual analog scales (VAS) and qualitative patient-reported outcomes, introduces additional variability. Pain perception is influenced by multiple factors (including psychological state), baseline pain sensitivity, and comorbid conditions such as anxiety or depression.
CBD in combination with Vegan diet helps a lot. The Indica would help put me to bed if I’m not feeling sleepy and keep me knocked out. ” 38 years (male Based on participant feedback), side effects experienced during medical cannabis treatment varied from an undesired high, stomach issues, ‘choking’ during vape usage, sleep impairment and reported overdose on Indica THC product. Medical cannabis is effective but does not enjoy being high. ” 65 years, male
Hospital visits accounted for 10.5% and unhealthy days for 18.3% due to random forests, implying that tree-based models added notable predictive insights in these scenarios. A “living systematic review” is a research methodology that continually updates itself with new evidence as it becomes accessible. Nowadays, cannabis is being considered similarly to how opioids were perceived several decades ago. Each person’s experience of pain varies significantly. Approximately 100 million adults in the United States confront chronic pain on a daily basis. Pain accounts for over half of all annual physician visits and incurs more than $600 billion each year in healthcare costs and lost productivity.